Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Hepatobiliary and Thromboembolic Events during Long-Term E.X.T.E.N.Ded Treatment with Eltrombopag in Adult Patients with Chronic Immune Thrombocytopenia (ITP)

Mansoor N. Saleh, James B Bussel, MD, Raymond SM Wong, Balkis Meddeb, Abdulgabar Salama, Ali El-Ali, Erhard Quebe-Fehling, PhD, Abderrahim Khelif

Blood (2016) 128 (22): 1368.

https://doi.org/10.1182/blood.V128.22.1368.1368

Published: 2016

Journal Articles

Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis

Raffaella Origa, Antonio Piga, MD, Immacolata Tartaglione, MD, Giuseppina Della Corte, Ali El-Ali, Jackie Han, Chiara Castiglioni, Gian Luca Forni, MD

Blood (2016) 128 (22): 2466.

https://doi.org/10.1182/blood.V128.22.2466.2466

Published: 2016

Journal Articles

Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study

Mansoor N. Saleh, James B. Bussel, MD, Abderrahim Khelif, Paul Burgess, Ali El-Ali, Anuja Roy, Victoria Barghout, Mei Sheng Duh, Kelly M. Grotzinger, Abdulgabar Salama

Blood (2016) 128 (22): 3742.

https://doi.org/10.1182/blood.V128.22.3742.3742

Published: 2016

Journal Articles

Efficacy of Eltrombopag in Adult East Asian and Non-East Asian Patients with Chronic Immune Thrombocytopenia (cITP): Results from the Extend Study

Raymond SM Wong, James B Bussel, MD, Mansoor N. Saleh, Abderrahim Khelif, Balkis Meddeb, Ali El-Ali, Erhard Quebe-Fehling, PhD, Abdulgabar Salama

Blood (2016) 128 (22): 4930.

https://doi.org/10.1182/blood.V128.22.4930.4930

Published: 2016

Journal Articles

Prospective, Multinational/Regional, Non-Interventional Study to Assess Treatment Practices in Anemia Patients Prone to Iron Overload: Results from the 3-Year Transfusional Hemosiderosis Registry (TORS)

Noppadol Siritanaratkul, Jong Wook Lee, Jun Ma, Mustafa Pehlivan, Elena Volodicheva, Qian Jiang, Fatiha Grifi, Bor-Sheng Ko, Raymond Wong, Vernon Louw, Abderrahim Khelif, Ali El-Ali, Jackie Han, Alfonso Losco, Osman Ilhan

Blood (2015) 126 (23): 2152.

https://doi.org/10.1182/blood.V126.23.2152.2152

Published: 2015

Journal Articles

Correlation of Hepatocyte Iron Score and Liver Iron Ratio with Alanine Aminotransferase in Patients with Beta Thalassemia Receiving Iron Chelation Therapy for at Least 3 Years

M Domenica Cappellini, Mohamed Bejaoui, Silverio Perrotta, MD, Leyla Agaoglu, Antonis Kattamis, Jackie Han, Ali El-Ali, John B Porter

Blood (2015) 126 (23): 2156.

https://doi.org/10.1182/blood.V126.23.2156.2156

Published: 2015

Journal Articles

Iron Chelation Therapy: A Review of the Literature on the Issues and Importance of Adherence to Treatment in Iron Overload

Vicky Huang, Cecilia Luini, Ali El-Ali, Sophia Kessabi

Blood (2015) 126 (23): 4748.

https://doi.org/10.1182/blood.V126.23.4748.4748

Published: 2015

Journal Articles

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

John B Porter, MD, Mohsen Elalfy, MD, Ali T Taher, MD, Lee Lee Chan, MD, Szu-Hee Lee, MD, Pranee Sutcharitchan, MD, Yesim Aydinok, MD, Subhashish Chakravarty, PhD, Ali El-Ali, MD, Amal El-Beshlawy, MD/Professor

Blood (2014) 124 (21): 52.

https://doi.org/10.1182/blood.V124.21.52.52

Published: 2014

Journal Articles

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

John B Porter, MD, Ali T Taher, MD PhD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen El-Alfy, MD, Ali El-Ali, MD, Subhashish Chakravarty, PhD, M Domenica Cappellini, MD

Blood (2014) 124 (21): 1366.

https://doi.org/10.1182/blood.V124.21.1366.1366

Published: 2014

Journal Articles

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

John B Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen Elalfy, MD, Ali El-Ali, MD, Nathalie Barbier, M Domenica Cappellini, MD

Blood (2014) 124 (21): 4040.

https://doi.org/10.1182/blood.V124.21.4040.4040

Published: 2014

Journal Articles

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

John Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Maria D Cappellini, Antonis Kattamis, MD, Ali El-Ali, MD, Nicolas Martin, MS, Dudley Pennell, MD, FRCP

Blood (2013) 122 (21): 1016.

https://doi.org/10.1182/blood.V122.21.1016.1016

Published: 2013

Journal Articles

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Amal El-Beshlawy, MD, Mohsen Elalfy, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Kai-Hsin Lin, MD, Yesim Aydinok, MD, Renzo Galanello, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 1028.

https://doi.org/10.1182/blood.V120.21.1028.1028

Published: 2012

Journal Articles

Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2–<6 Years At Enrollment.

Elliott Vichinsky, MD, Amal El-Beshlawy, MD, Azzam Alzoebie, MD, Francoise Bernaudin, MD, Suzanne Koussa, MD, Thirachit Chotsampancharoen, MD, Ali El-Ali, MD, Caroline Arrowsmith, Nicolas Martin, MS, Mohsen El-Alfy, MD

Blood (2012) 120 (21): 2125.

https://doi.org/10.1182/blood.V120.21.2125.2125

Published: 2012

Journal Articles

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

John B Porter, MD, Mohsen Elalfy, MD, Vip Viprakasit, MD, DPhil, Stephane Giraudier, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 2126.

https://doi.org/10.1182/blood.V120.21.2126.2126

Published: 2012

Journal Articles

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

M Domenica Cappellini, MD, Amal El-Beshlawy, MD, John B Porter, MD, Antonis Kattamis, MD, PhD, Kerry Taylor, MD, Christian Rose, Vernon J Louw, MD, Ali El-Ali, MD, Nicolas Martin, MS, Norbert Gattermann, MD

Blood (2012) 120 (21): 5182.

https://doi.org/10.1182/blood.V120.21.5182.5182

Published: 2012

Journal Articles

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Jong Wook Lee, MD, PhD, Sung-Soo Yoon, MD, PhD, Zhi Xiang Shen, MD, Arnold Ganser, MD, Hui-Chi Hsu, MD, Ali El-Ali, MD, Dany Habr, MD, Bernard Roubert, PhD, John B. Porter, MD, on behalf of the EPIC study investigators

Blood (2011) 118 (21): 1344.

https://doi.org/10.1182/blood.V118.21.1344.1344

Published: 2011

NARROW

Hepatobiliary and Thromboembolic Events during Long-Term E.X.T.E.N.Ded Treatment with Eltrombopag in Adult Patients with Chronic Immune Thrombocytopenia (ITP)

Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis

Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study

Efficacy of Eltrombopag in Adult East Asian and Non-East Asian Patients with Chronic Immune Thrombocytopenia (cITP): Results from the Extend Study

Prospective, Multinational/Regional, Non-Interventional Study to Assess Treatment Practices in Anemia Patients Prone to Iron Overload: Results from the 3-Year Transfusional Hemosiderosis Registry (TORS)

Correlation of Hepatocyte Iron Score and Liver Iron Ratio with Alanine Aminotransferase in Patients with Beta Thalassemia Receiving Iron Chelation Therapy for at Least 3 Years

Iron Chelation Therapy: A Review of the Literature on the Issues and Importance of Adherence to Treatment in Iron Overload

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2–<6 Years At Enrollment.

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only